Trial Profile
Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Diabetic foot ulcer
- Focus Proof of concept; Therapeutic Use
- Acronyms InTREPiD
- 05 Dec 2023 Status changed from recruiting to discontinued.
- 05 Nov 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2023.
- 16 Jan 2020 Planned End Date changed from 28 Feb 2022 to 1 Sep 2023.